Company: ARVN
Filing Date: 2025-01-10
Form Type: 8-K
Source: 0001655759-25-000004
Chunk: 2

Company: ARVINAS, INC.
Filing Date: 2025-01-10
Form: 8-K
Item: Item 8.01
Chunk 2
---
 ARV-393, the Company’s PROTAC targeting the B-cell lymphoma 6, in patients with B-cell lymphomas (NCT06393738); and

• file an Investigational New Drug (“ IND”) application for the Company’s PROTAC Kirsten rat sarcoma (“ KRAS”) G12D degrader.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential plans related to and timing of initiation of clinical trials and presentation of data from clinical trials of vepdegestrant, ARV-393 and ARV-102 as well as filing of an IND for the Company’s KRAS G12D degrader. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The word “plan,” and similar expressions are intended to identify forward-looking

statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including the important factors discussed the important factors discussed in the “ Risk Factors” sections contained in the Company’s quarterly and annual reports on file with the U. S. Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K reflect the Company’s current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.